CGT Catapult has joined a new consortium - led by UK ATMP developer Achilles Therapeutics and which includes Leibniz University Hannover (Hannover) as project coordinator and the Fundacion para la Investigacion del Hospital Universitario la Fe de la Comunidad Valenciana (Valencia) – with the goal of developing a smart bioprocessing manufacturing platform (bioreactor) for personalised cell therapies. Click to read more.
BIOCARDIA REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. - August 10, 2022 -BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and. | August 10, 2022
London, 22 July 2022 – Cell and Gene Therapy Catapult (CGT Catapult) today announced the launch of a new consortium that will drive forward innovation and advancement in the manufacturing of personalised cell therapies. The new consortium – led by UK ATMP developer Achilles Therapeutics and which al.
MILAN, Italy and NEW YORK, May 13, 2022 Genenta Science , a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer,.